Drug Search Results
More Filters [+]

Rocuronium bromide

Alternative Names: rocuronium bromide, org 9426, zemuron, eslax
Latest Update: 2024-05-07
Latest Update Note: Clinical Trial Update

Product Description

Rocuronium is a new nondepolarizing neuromuscular blocking drug. Its onset of action is comparable to that of succinylcholine, with good-to-excellent intubating conditions possible 1 minute after doses two times the ED95 (600 micrograms/kg). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8122487/)

Mechanisms of Action: nAChR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Anastesia Related

Known Adverse Events: Hypertension | Hypotension

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rocuronium bromide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events